Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

toothbrush

- PMLiVE

GSK’s linerixibat shows promise in phase 3 primary biliary cholangitis trial

An estimated 510,000 people will be diagnosed with the rare liver disease globally by 2030

- PMLiVE

FDA approves Shorla Oncology’s Imkeldi to treat leukaemia and other cancers

The solution is an advanced liquid formulation of the tyrosine kinase inhibitor imatinib mesylate

- PMLiVE

All hands on deck

We all need to push harder towards environmental sustainability goals

David W. Miller

Innovating Differently: A Conversation with David W. Miller, CEO of Genesis Research Group

A recent interview with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition...

Genesis Research Group

- PMLiVE

Roche expands cell therapy capabilities with $1.5bn Poseida acquisition

The deal includes a BCMA-targeting allogeneic CAR-T therapy candidate for multiple myeloma

- PMLiVE

AstraZeneca announces $3.5bn US investment to boost research and manufacturing

The commitment is part of the company’s ambition to achieve $80bn in total revenue by 2030

- PMLiVE

Ipsen shares positive three-year results for Iqirvo in primary biliary cholangitis

The rare liver disease affects approximately 100,000 people in the US

- PMLiVE

Langland appoints Gemma Cathcart as managing partner

Cathcart most recently served as managing director for global marketing at Avalere Health

- PMLiVE

Why the patient voice is the secret to re-energising the healthcare sector

The challenges facing the UK’s healthcare system and why putting the patient voice at the heart of our work is key

- PMLiVE

Education, AI and More at ASH 2024

Medscape will showcase eight educational symposia and three posters at ASH 2024, highlighting advancements in hematology and oncology education. The presentations will reflect on the impact of last year's programs,...

Medscape Education

- PMLiVE

Novartis and Ratio enter radiotherapeutics partnership worth $745m

The companies will focus on advancing a candidate for SSTR2-expressing tumours

- PMLiVE

J&J and Protagonist share promising phase 3 results for icotrokinra in plaque psoriasis

More than 125 million people globally are estimated to be living with the skin disorder

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links